OTCMKTS:OXBDF Oxford Biomedica (OXBDF) Stock Forecast, Price & News $5.47 -0.04 (-0.64%) (As of 05/26/2023 08:48 PM ET) Add Compare Share Share Today's Range$5.47▼$5.4750-Day Range$5.17▼$5.6352-Week Range$3.35▼$6.70Volume5,000 shsAverage Volume11,770 shsMarket Capitalization$526.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsHeadlinesShort InterestProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest About Oxford Biomedica (OTCMKTS:OXBDF) StockOxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.Read More Receive OXBDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXBDF Stock News HeadlinesMay 6, 2023 | americanbankingnews.comCantor Fitzgerald Begins Coverage on Oxford Biomedica (OTCMKTS:OXBDF)April 30, 2023 | americanbankingnews.comOxford Biomedica plc Forecasted to Earn FY2023 Earnings of ($0.58) Per Share (OTCMKTS:OXBDF)May 29, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowApril 27, 2023 | americanbankingnews.comOxford Biomedica (OTCMKTS:OXBDF) Receives Buy Rating from HC WainwrightFebruary 20, 2023 | finance.yahoo.comDr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023January 30, 2023 | finance.yahoo.comThe past year for Oxford Biomedica (LON:OXB) investors has not been profitableNovember 14, 2022 | finance.yahoo.comOxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 millionSeptember 15, 2022 | lse.co.ukOxford BioMedica swings to interim loss as costs climb, revenue fallsMay 29, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowAugust 19, 2022 | finance.yahoo.comOxford Biomedica (LON:OXB) shareholders have endured a 66% loss from investing in the stock a year agoJuly 26, 2022 | lse.co.ukOxford BioMedica begins new project and signs license agreementJuly 26, 2022 | finance.yahoo.comOxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T TherapyJuly 16, 2022 | finance.yahoo.comOxford Biomedica plc's (LON:OXB) Intrinsic Value Is Potentially 20% Below Its Share PriceJuly 1, 2022 | lse.co.ukSMALL-CAP WINNERS & LOSERS: Oxford BioMedica rises on AstraZeneca dealJuly 1, 2022 | seekingalpha.comAstraZeneca signs new three-year deal with Oxford Biomedica for COVID shotJuly 1, 2022 | finance.yahoo.comOxford BioMedica extends Covid vaccine deal with AstraZenecaJune 14, 2022 | lse.co.ukUS FDA lifts clinical hold on Oxford BioMedica partner's trialMay 15, 2022 | finance.yahoo.comCould The Market Be Wrong About Oxford Biomedica plc (LON:OXB) Given Its Attractive Financial Prospects?April 20, 2022 | seekingalpha.comOxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: PrelimApril 20, 2022 | lse.co.ukOxford BioMedica shares fall as warns on 2022 amid Covid jab pauseApril 20, 2022 | marketwatch.comOxford BioMedica Sees Lower 2022 Revenue on Suspension of Covid-19 Vaccine With AstraZenecaApril 20, 2022 | ft.comOxford BioMedica warns revenue will be hit by AstraZeneca jab uncertaintyApril 20, 2022 | uk.finance.yahoo.comOxford Biomedica warns on sales after pausing AstraZeneca COVID vaccineApril 20, 2022 | finance.yahoo.comOxford Biomedica Preliminary ResultsMarch 13, 2022 | seekingalpha.comOxford Biomedica completes deal with Homology Medicines to set up 1st US subsidiaryMarch 10, 2022 | finance.yahoo.comHomology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford BiomedicaJanuary 28, 2022 | lse.co.ukUPDATE: Oxford BioMedica raises GBP80 million via placingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OXBDF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXBDF Company Calendar Today5/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Private households Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:OXBDF Previous SymbolNASDAQ:OXBDF CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone44-18-6578-3000FaxN/AEmployees815Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$112.66 million Price / Sales4.67 Cash Flow$0.06 per share Price / Cash Flow91.07 Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares96,260,000Free FloatN/AMarket Cap$526.06 million OptionableNot Optionable Beta1.13 Key ExecutivesDr. Roch DoliveuxInterim CEO & ChairmanMr. Stuart Paynter (Age 49)CFO, Company Sec. & Director Comp: $910.2kMr. Nick PageChief Operations OfficerDr. James Miskin Ph.D.Chief Technical OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerMr. Matthew TreagusChief Information OfficerSophia BolhassanHead of Investor RelationsMs. Natalie Louise WalterGen. CounselDr. Jason Slingsby MBAChief Bus. & Corp. Devel. OfficerMs. Sarah MacleodHead of CommunicationsMore ExecutivesKey CompetitorsSemperit AktiengesellschaftOTCMKTS:SEIGYAurora CannabisOTCMKTS:ACBFFPharma MarOTCMKTS:PHMMFClinigen GroupOTCMKTS:CLIGFAgenusNASDAQ:AGENView All Competitors OXBDF Stock - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OXBDF shares. View OXBDF analyst ratings or view top-rated stocks. How have OXBDF shares performed in 2023? Oxford Biomedica's stock was trading at $5.22 at the beginning of 2023. Since then, OXBDF shares have increased by 4.7% and is now trading at $5.4650. View the best growth stocks for 2023 here. What is Oxford Biomedica's stock symbol? Oxford Biomedica trades on the OTCMKTS under the ticker symbol "OXBDF." How do I buy shares of Oxford Biomedica? Shares of OXBDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oxford Biomedica's stock price today? One share of OXBDF stock can currently be purchased for approximately $5.47. How much money does Oxford Biomedica make? Oxford Biomedica (OTCMKTS:OXBDF) has a market capitalization of $526.06 million and generates $112.66 million in revenue each year. How many employees does Oxford Biomedica have? The company employs 815 workers across the globe. How can I contact Oxford Biomedica? Oxford Biomedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The official website for the company is www.oxfordbiomedica.co.uk. The company can be reached via phone at 44-18-6578-3000. This page (OTCMKTS:OXBDF) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.